$1.22
arrow_drop_up4.27%Key Stats | |
---|---|
Open | $1.10 |
Prev. Close | $1.11 |
EPS | -1.80 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $136.16M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.10 | 1.21 |
52 Week Range | 0.81 | 5.19 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.80 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
Invivyd to Participate at the Jefferies Global Healthcare Conference
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
Invivyd Elects Two New Independent Members to its Board of Directors